founder evidence room
HSV care · support, not a cure · investor readinessyou've built the hard part. now we build the proof.
MUDE already owns what most brands never get — a founder-native, shame-free, stigma-fluent read of the room, a finished brand, and a real content moat. The missing piece is proof — and proof is buildable. The reframe is simple: don't raise on a story, raise on a curve.
the honest read
lock four foundations before spending into launch.
MUDE has the hard-to-buy assets: founder-market fit, a sharp stigma-and-care insight, a credible voice, deep education material, advisor momentum. Before spending into ads, launch, or investor meetings, four foundations need locking — what you can legally claim, what you can sell right now, how you capture demand safely, and how you measure results.
{{ f.body }}
{{ f.badge }}two questions decide where we start.
{{ q.body }}
One caution — a claim being in the deck is not the same as a claim being approved. Any "legal/medical approved" language needs an owner, scope, artifact, channel, and date before it reaches a customer or investor.
what investors are really asking
can this category be acquired, trusted, and monetized without breaking the rules?
These are the real objections behind a pause at this stage — surfaced by reading the entire data room, not skimming the deck. None is a dead end. For every gap, there is a clear place ASON steps in.
{{ g.body }}
where ASON comes in → {{ g.ason }}
market reality
not no competitors. fragmented substitutes.
Rx telehealth, OTC cold-sore products, supplements, education, clinics, and sexual wellness already serve pieces of the job. MUDE's investor-safe wedge is not absence of competition — it is becoming the trusted modern care system that connects evidence-led support, stigma-fluent education, discreet commerce, and community trust.
{{ s.body }}
a fuller read: MUDE's swot.
Beyond the substitute map — strengths to lean on, weaknesses to close, openings to take, and threats to manage.
{{ w.body }}
the market is not empty. it is waiting for someone disciplined enough to connect the pieces.
live digital footprint
the quiet footprint is a chance to launch clean.
MUDE's public footprint appears intentionally quiet. That protects the brand from premature claim exposure — but it also means the current surface does not yet prove discoverability, compliant acquisition, or demand capture. This is the moment to turn the quiet period into a controlled launch advantage.
Point-in-time external audit from 2026-06-20. Alexandra should flag anything already changed; re-check public pages, social posts, staged pages, and ad surfaces before launch.
claim control
support, not cure. evidence, not overreach.
ASON can triage and rewrite claims. ASON cannot approve legal or medical language — final approval belongs to Alexandra, counsel, and named advisors. Because the context is HSV, even general support language can become an implied disease claim beside product, creator, or ad context.
Balm classification is a separate question to settle: don't frame the balm as cold-sore treatment or support until counsel confirms whether it is cosmetic skincare, an OTC drug, or another reviewed category.
the market opportunity
a big market is not the same as reachable demand.
Investors want three things, in plain terms: how big the whole market is, the slice MUDE can realistically serve, and the beachhead it can actually win first. The category is real and growing — the work is showing how MUDE narrows from "huge" to "winnable."
The honest gap today: the deck cites the big top-down number, but the bottom-up story — who MUDE reaches, at what conversion, at what price — isn't built yet. That is exactly what the proof sprint produces, replacing estimates with MUDE's own measured numbers.
Category figures are third-party estimates (Grand View Research, via the deck), not MUDE traction. Servable-market and year-one figures will be built from real data and clearly labeled before any investor use.
privacy-safe demand
capture intent before diagnosis data.
In this category, the first conversion should not force people to declare HSV status. Start with education, discreet updates, early access, and journey needs. Collect sensitive health details only when there is a reviewed reason, consent structure, and privacy policy.
{{ fn.body }}
paid & platform reality
paid can scale this. it should not lead it.
HSV, supplement, and sexual-wellness campaigns are policy-sensitive. Early traction should lean on organic, creator, SEO, and email; paid becomes a controlled test only after claims, landing pages, and account questions are settled. This grid is the honest answer to "can you even advertise this?"
Platform policies move; every channel here is anchored to live policy links in the appendix and re-checked before spend. Paid is additive, never load-bearing.
creator activation
feedback first. endorsement later.
The Room & Advocates work identifies the trust map. ASON turns that map into careful relationship paths: trust risk, first ask, proof needed, and possible paths by advocate type.
{{ a.body }}
product & offer readiness
do not sell proof the product cannot support.
Before any market-facing work expands, MUDE needs one clean operating answer: can the company ship, pre-sell, reserve, or only invite people into a waitlist? The deck suggests balm is nearest-term and supplements come later — so the safest proof sprint is likely balm-led or waitlist-led until readiness is confirmed.
{{ rd.body }}
commercial engine
audit finds the gaps. creator-led gtm turns them into measurable tests.
ASON's highest-leverage role is not only naming the diligence risk — it is operating the social, content, and creator system that moves MUDE from private trust to measured demand: who carries the message, what they can safely say, how outreach is sequenced, and which signals become investor evidence.
{{ e.body }}
ASON recommendation · designed operating layer, not executed traction · no creator agreement, claim approval, SKU readiness, or revenue outcome is implied until source-labeled evidence exists.
from read to traction to raise
the path forward is a series of decisions, not promises.
This should not make MUDE sound farther along than it is. It is the operating path: each step opens only when the prior evidence exists, so the company never turns an assumption into an investor claim too early.
{{ p.body }}
Planning architecture only · not a launch schedule, financing promise, revenue projection, legal opinion, or investment recommendation.
how ason engages
value first. proof now. scale when the round closes.
This is not another agency retainer billed against an unproven launch. Treat the next phase as proof capital: start lean, produce the artifacts investors need to see, and keep any larger growth engine conditional on what the proof shows.
{{ om.body }}
don't raise on a deck. raise on a curve — and let the proof do the pitching.
Engagement shape and commercial terms are indicative only, to be papered in a short SOW and advisory agreement. Not legal, financial, or investment advice.
only what alexandra must decide
keep the founder asks narrow.
ASON brings the proof scaffolding. Alexandra only confirms the things ASON cannot responsibly decide for MUDE. Everything else can move now.
{{ cf.body }}
where we go from here
care like this is rare. proof like this gets funded.
MUDE already has the brand, the insight, and the moat. The next move isn't a better deck — it's evidence. ASON can stand up the proof, keep it compliant, and be ready to expand when the round and the evidence support it. One working session sets it in motion.
back to the top ↑appendix — sources & substantiation
dated anchors behind the read.
Public sources checked 2026-06-20 that anchor the market, platform, and compliance points in this readout. These are source anchors, not legal approvals. The internal working files behind each section are listed below them.
market anchors
claims & channel anchors
Internal working files (ASON, not for external distribution):